Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TARDBP pseudogene 4 (abbreviated TARDBPP4) is presumed to be a pseudogene of the TARDBP gene based on nomenclature and genomic databases. The canonical gene, TARDBP, encodes the RNA/DNA-binding protein TDP-43, which is widely expressed and involved in transcription regulation, RNA splicing, and several cellular processes, and is known for its pathogenic aggregation in neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia[1][4][6]. TARDBP pseudogene 4, however, is not considered to encode a functional protein and is not recognized as a molecular target or therapeutic receptor; current scientific databases provide no evidence of a biological, pathological, or therapeutic role for this pseudogene[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TAR DNA-binding protein pseudogene 4 (TARDBPP4).